# FinanceBench Benchmark Report: `mistral_glm`

- **Date**: 2026-09-02 06:56:34 UTC
- **Agent LLM**: `glm_5.2@openrouter`
- **Judge LLM**: `DeepSeek-V4-Pro-0813@openrouter`
- **Total Questions Evaluated**: 150

## Summary Metrics

| Metric | Value |
|---|---|
| **Exact Correct** | 137 (91.3%) |
| **Correct or Partial** | 144 (96.0%) |
| **Incorrect** | 6 (4.0%) |
| **Groundedness Rate** | 145 / 150 (96.7%) |
| **Numeric Match Rate** | 92.6% (108 numeric questions) |
| **Avg Tool Calls / Question** | 6.11 |
| **Avg Input Tokens / Question** | 104,039 |
| **Avg Output Tokens / Question** | 2,782 |

## Results by Document

| Document | Questions | Correct | Partial | Incorrect | Accuracy (Lenient) |
|---|---|---|---|---|---|
| `3M_2018_10K` | 2 | 2 | 0 | 0 | 100.0% |
| `3M_2022_10K` | 3 | 3 | 0 | 0 | 100.0% |
| `3M_2023Q2_10Q` | 3 | 3 | 0 | 0 | 100.0% |
| `ACTIVISIONBLIZZARD_2019_10K` | 2 | 2 | 0 | 0 | 100.0% |
| `ADOBE_2015_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `ADOBE_2016_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `ADOBE_2017_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `ADOBE_2022_10K` | 2 | 2 | 0 | 0 | 100.0% |
| `AES_2022_10K` | 3 | 3 | 0 | 0 | 100.0% |
| `AMAZON_2017_10K` | 2 | 2 | 0 | 0 | 100.0% |
| `AMAZON_2019_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `AMCOR_2020_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `AMCOR_2022_8K_dated-2022-07-01` | 1 | 1 | 0 | 0 | 100.0% |
| `AMCOR_2023Q2_10Q` | 1 | 0 | 1 | 0 | 100.0% |
| `AMCOR_2023Q4_EARNINGS` | 2 | 2 | 0 | 0 | 100.0% |
| `AMCOR_2023_10K` | 4 | 4 | 0 | 0 | 100.0% |
| `AMD_2015_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `AMD_2022_10K` | 7 | 7 | 0 | 0 | 100.0% |
| `AMERICANEXPRESS_2022_10K` | 7 | 7 | 0 | 0 | 100.0% |
| `AMERICANWATERWORKS_2020_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `AMERICANWATERWORKS_2021_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `AMERICANWATERWORKS_2022_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `BESTBUY_2017_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `BESTBUY_2019_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `BESTBUY_2023_10K` | 3 | 3 | 0 | 0 | 100.0% |
| `BESTBUY_2024Q2_10Q` | 3 | 3 | 0 | 0 | 100.0% |
| `BLOCK_2016_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `BLOCK_2020_10K` | 2 | 2 | 0 | 0 | 100.0% |
| `BOEING_2018_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `BOEING_2022_10K` | 7 | 5 | 2 | 0 | 100.0% |
| `COCACOLA_2017_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `COCACOLA_2021_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `COCACOLA_2022_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `CORNING_2020_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `CORNING_2021_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `CORNING_2022_10K` | 2 | 1 | 1 | 0 | 100.0% |
| `COSTCO_2021_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `CVSHEALTH_2018_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `CVSHEALTH_2022_10K` | 3 | 2 | 1 | 0 | 100.0% |
| `FOOTLOCKER_2022_8K_dated-2022-05-20` | 1 | 1 | 0 | 0 | 100.0% |
| `FOOTLOCKER_2022_8K_dated_2022-08-19` | 1 | 1 | 0 | 0 | 100.0% |
| `GENERALMILLS_2019_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `GENERALMILLS_2020_10K` | 2 | 2 | 0 | 0 | 100.0% |
| `GENERALMILLS_2022_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `JOHNSON_JOHNSON_2022Q4_EARNINGS` | 2 | 1 | 0 | 1 | 50.0% |
| `JOHNSON_JOHNSON_2022_10K` | 3 | 3 | 0 | 0 | 100.0% |
| `JOHNSON_JOHNSON_2023Q2_EARNINGS` | 1 | 1 | 0 | 0 | 100.0% |
| `JOHNSON_JOHNSON_2023_8K_dated-2023-08-30` | 3 | 3 | 0 | 0 | 100.0% |
| `JPMORGAN_2021Q1_10Q` | 2 | 1 | 1 | 0 | 100.0% |
| `JPMORGAN_2022Q2_10Q` | 1 | 1 | 0 | 0 | 100.0% |
| `JPMORGAN_2022_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `JPMORGAN_2023Q2_10Q` | 1 | 1 | 0 | 0 | 100.0% |
| `KRAFTHEINZ_2019_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `LOCKHEEDMARTIN_2020_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `LOCKHEEDMARTIN_2021_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `LOCKHEEDMARTIN_2022_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `MGMRESORTS_2018_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `MGMRESORTS_2020_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `MGMRESORTS_2022Q4_EARNINGS` | 3 | 2 | 0 | 1 | 66.7% |
| `MGMRESORTS_2022_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `MGMRESORTS_2023Q2_10Q` | 1 | 1 | 0 | 0 | 100.0% |
| `MICROSOFT_2016_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `MICROSOFT_2023_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `NETFLIX_2015_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `NETFLIX_2017_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `NIKE_2018_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `NIKE_2019_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `NIKE_2021_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `NIKE_2023_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `PAYPAL_2022_10K` | 1 | 0 | 1 | 0 | 100.0% |
| `PEPSICO_2021_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `PEPSICO_2022_10K` | 5 | 4 | 0 | 1 | 80.0% |
| `PEPSICO_2023Q1_EARNINGS` | 2 | 2 | 0 | 0 | 100.0% |
| `PEPSICO_2023_8K_dated-2023-05-05` | 1 | 1 | 0 | 0 | 100.0% |
| `PEPSICO_2023_8K_dated-2023-05-30` | 2 | 2 | 0 | 0 | 100.0% |
| `PFIZER_2021_10K` | 3 | 3 | 0 | 0 | 100.0% |
| `Pfizer_2023Q2_10Q` | 3 | 1 | 0 | 2 | 33.3% |
| `ULTABEAUTY_2023Q4_EARNINGS` | 4 | 3 | 0 | 1 | 75.0% |
| `ULTABEAUTY_2023_10K` | 2 | 2 | 0 | 0 | 100.0% |
| `VERIZON_2021_10K` | 2 | 2 | 0 | 0 | 100.0% |
| `VERIZON_2022_10K` | 3 | 3 | 0 | 0 | 100.0% |
| `WALMART_2018_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `WALMART_2019_10K` | 1 | 1 | 0 | 0 | 100.0% |
| `WALMART_2020_10K` | 1 | 1 | 0 | 0 | 100.0% |

## Results by Question Type / Reasoning

| Category | Questions | Correct | Partial | Incorrect | Accuracy (Lenient) |
|---|---|---|---|---|---|
| Information extraction | 31 | 30 | 0 | 1 | 96.8% |
| Information extraction OR Logical reasoning | 1 | 1 | 0 | 0 | 100.0% |
| Information extraction OR Logical reasoning OR | 1 | 1 | 0 | 0 | 100.0% |
| Logical reasoning (based on numerical reasoning) | 5 | 4 | 1 | 0 | 100.0% |
| Logical reasoning (based on numerical reasoning) OR Logical reasoning | 5 | 5 | 0 | 0 | 100.0% |
| Logical reasoning (based on numerical reasoning) OR Numerical reasoning OR Logical reasoning | 4 | 4 | 0 | 0 | 100.0% |
| Numerical reasoning | 43 | 43 | 0 | 0 | 100.0% |
| Numerical reasoning OR Logical reasoning | 6 | 4 | 2 | 0 | 100.0% |
| Numerical reasoning OR information extraction | 4 | 4 | 0 | 0 | 100.0% |
| novel-generated | 50 | 41 | 4 | 5 | 90.0% |

## Non-Perfect Questions Analysis

### `financebench_id_00005` — CORNING_2022_10K (PARTIAL)

- **Question**: Does Corning have positive working capital based on FY2022 data? If working capital is not a useful or relevant metric for this company, then please state that and explain why.
- **Gold Answer**: Yes. Corning had a positive working capital amount of $831 million by FY 2022 close. This answer considers only operating current assets and current liabilities that were clearly shown in the balance sheet.
- **Agent Answer**: ## Answer

**Yes, Corning has positive working capital in FY2022.** Working capital is a relevant and useful metric for Corning, as it is a manufacturing company (glass, ceramics, optical fiber, display technologies) with conventional inventory, receivables, and payables — not a financial institution where the metric would be meaningless.

### Calculation (FY2022, as of December 31, 2022)

| Line item | Amount ($ millions) |
|---|---|
| Total current assets | $7,453 |
| Total current liabilities | $5,175 |
| **Working capital** | **$2,278** |

**Working Capital = Current Assets − Current Liabilities = $7,453M − $5,175M = $2,278M**

### Supporting detail (from the Consolidated Balance Sheet)

Current assets ($7,453M) comprised:
- Cash and cash equivalents: $1,671M
- Trade accounts receivable, net: $1,721M
- Inventories: $2,904M
- Other current assets: $1,157M

Current liabilities ($5,175M) comprised:
- Current portion of long-term debt and short-term borrowings: $224M
- Accounts payable: $1,804M
- Other accrued liabilities: $3,147M

### Conclusion

Corning's FY2022 working capital is **positive at approximately $2,278 million**, indicating the company's short-term assets comfortably exceed its short-term obligations. The metric is meaningful here because Corning is an industrial manufacturer with a standard operating cycle (raw materials → inventory → receivables → cash), so the current asset/current liability relationship is a valid indicator of short-term liquidity.

*Citation: CORNING_2022_10K_pdf.md [cb6bb56af29ce129::183] — Consolidated Balance Sheets, December 31, 2022.*
- **Judge Rationale**: The agent correctly concludes Corning had positive working capital, but its $2,278 million standard current-assets-minus-current-liabilities figure does not match the gold answer's $831 million operating working capital figure.
- **Numeric Match**: False
- **Groundedness**: grounded

### `financebench_id_00080` — PAYPAL_2022_10K (PARTIAL)

- **Question**: Does Paypal have positive working capital based on FY2022 data? If working capital is not a useful or relevant metric for this company, then please state that and explain why.
- **Gold Answer**: Yes. Paypal has a positive working capital of $ 1.6Bn as of FY2022 end.
- **Agent Answer**: ## Answer

**Yes — on a face-value basis PayPal reports positive working capital for FY2022, but working capital is not a particularly meaningful metric for this company.** The headline figure is distorted by the large pass-through customer-fund balances that dominate both sides of the balance sheet.

### Calculation (as reported on the face of the Consolidated Balance Sheet, Dec 31, 2022)

| Item | $ millions |
|---|---|
| Total current assets | 57,517 |
| Total current liabilities | 45,101 |
| **Working capital** | **12,416 (positive)** |

Source: PAYPAL_2022_10K_pdf.md [00d1c44284cbf5be::152]

### Why working capital is not a useful metric for PayPal

PayPal is a payments/money-services company, and the largest line items in both current assets and current liabilities are **customer-held funds that PayPal custodies in a fiduciary capacity**, not operating working capital:

- **Funds receivable and customer accounts** (current asset): **$36,357M** — ~63% of total current assets
- **Funds payable and amounts due to customers** (current liability): **$40,107M** — ~89% of total current liabilities

These two balances are essentially mirror images of each other: PayPal collects money from payers, holds it, and remits it to payees. They move in lockstep with transaction volumes and customer balances, not with PayPal's own operating cycle. Including them inflates both sides of the working-capital equation by tens of billions of dollars and makes the headline number a poor indicator of PayPal's short-term liquidity or operational efficiency.

### Adjusted view (excluding customer pass-through funds)

| Item | $ millions |
|---|---|
| Current assets ex. funds receivable & customer accounts (57,517 − 36,357) | 21,160 |
| Current liabilities ex. funds payable & amounts due to customers (45,101 − 40,107) | 4,994 |
| **Adjusted working capital** | **16,166 (positive)** |

Even after stripping out the customer-fund pass-throughs, working capital remains positive — but analysts of payments companies typically rely on **liquidity metrics tied to corporate cash, available credit facilities, and free cash flow** rather than traditional working capital, because the latter is structurally distorted by the customer-balances dynamic described above. PayPal's own MD&A discusses liquidity in terms of cash, investments, and available credit facilities rather than working capital (PAYPAL_2022_10K_pdf.md [00d1c44284cbf5be::105]–[00d1c44284cbf5be::113]).

### Bottom line
- **Face-value working capital (FY2022): +$12,416M (positive).**
- **Relevance:** Low. The metric is dominated by ~$36–40B of customer pass-through funds on both sides of the balance sheet, so it does not reflect PayPal's operating liquidity. A more informative read is corporate cash & investments ($7,776M cash + $3,092M short-term investments + $5,018M long-term investments ≈ $15.9B) against corporate debt and operating obligations.
- **Judge Rationale**: The agent correctly concludes PayPal has positive working capital, but its reported $12,416M face-value or $16,166M adjusted working capital differs materially from the gold figure of $1.6Bn, so the direction is right but the amount does not match.
- **Numeric Match**: False
- **Groundedness**: grounded

### `financebench_id_00283` — Pfizer_2023Q2_10Q (INCORRECT)

- **Question**: How much does Pfizer expect to pay to spin off Upjohn in the future in USD million?
- **Gold Answer**: 77.78
- **Agent Answer**: I'll research this question about Pfizer's Upjohn spin-off costs. Let me start by exploring the document graph.I found Pfizer documents. The Upjohn spin-off was completed in 2020, so the 2021 10-K would discuss it. Let me explore the Pfizer document structure.I see the "Discontinued Operations" section (id 113) and "Restructuring Charges" sections. Let me search for "Upjohn" and check the key sections.The Discontinued Operations section points to Note 2B. Let me read that section and search more specifically for Upjohn/Viatris transaction details.The "B. Divestitures" section appears to just have a header. Let me check adjacent sections and the business development section that may contain the Upjohn details.I found a key detail — a $277 million payment to Viatris in 2021. Let me look at the adjacent section for more complete context about future expected payments.Let me search more specifically and look at the restructuring/other costs sections that may detail Upjohn spin-off costs.I found the key section "Upjohn Separation and Combination with Mylan" (id 188). Let me read it along with the related discontinued operations components section.I found the answer. Let me verify the key detail in section 189 about the future payment related to the Upjohn spin-off.

## Answer

**Pfizer expected to pay $277 million to Viatris in the future related to the Upjohn spin-off.**

### Supporting Evidence

According to Pfizer's 2021 Form 10-K (Note 2B. Divestitures), in connection with the Upjohn Separation and Combination with Mylan (which formed Viatris, completed November 16, 2020), Pfizer and Viatris entered into various separation agreements. The filing states:

> "...a **$277 million payment to Viatris made in 2021** pursuant to terms of the separation agreement, which is reported in *Other financing activities, net*, and **was recorded as a payable to Viatris in *Other current liabilities* as of December 31, 2020**."

`[654f9494117719b6::189]` (PFIZER_2021_10K_pdf.md)

### Context
- The Upjohn spin-off was completed on November 16, 2020, as an all-stock Reverse Morris Trust transaction combining the Upjohn Business with Mylan to form Viatris `[654f9494117719b6::188]`.
- As of December 31, 2020, Pfizer had recorded a **$277 million payable to Viatris** in Other current liabilities, representing the future cash payment expected to be made under the separation agreement. This payment was subsequently made in 2021 `[654f9494117719b6::189]`.

**Answer: $277 million**
- **Judge Rationale**: The agent cites a $277 million payable to Viatris from the 2021 10-K, whereas the gold answer is $77.78 million in remaining Upjohn separation costs, so the amounts do not match.
- **Numeric Match**: False
- **Groundedness**: grounded

### `financebench_id_00494` — BOEING_2022_10K (PARTIAL)

- **Question**: What production rate changes is Boeing forecasting for FY2023?
- **Gold Answer**: Boeing forecasts an increase in the production rates for the 737, 777X and 787 aircrafts in 2023.
- **Agent Answer**: I'll investigate Boeing's FY2023 production rate forecasts. The most relevant document would be the BOEING_2022_10K (filed in early 2023, which would contain forward-looking statements about 2023 production). Let me explore its structure.I'll search for production rate forecasts in the Boeing 2022 10-K (the filing that would contain FY2023 forecasts).The initial content doesn't directly cover production rate forecasts. Let me search more specifically for production rate details in the Commercial Airplanes and MD&A sections.Let me search for more specific terms and look at additional sections that may contain forward-looking production rate forecasts.Let me look at the Business Environment and Trends section under the Commercial Airplanes segment which typically contains production rate forecasts.Let me look at the Overview section of the MD&A and additional sections that typically contain production rate forecasts.I've found references to ramping up production but not specific rate numbers yet. Let me search for more specific terms about production rates and also look at the Commercial Airplanes Segment section in Item 1 more thoroughly.Let me check the Commercial Airplanes Segment description more thoroughly and search for specific production rate terminology.I found the production rate forecasts in the Program Highlights section. Let me compile the complete answer based on what I've read.

## Boeing's FY2023 Production Rate Forecasts

Based on Boeing's 2022 10-K filing (filed January 27, 2023), the company disclosed the following production rate forecasts for FY2023 across its Commercial Airplanes programs:

### 737 Program
- **Current rate:** 31 per month (increased during 2022)
- **FY2023 forecast:** "expect to implement further gradual production rate increases based on market demand and supply chain capacity" — i.e., continued gradual increases above the 31/month rate, contingent on market demand and supply chain capacity ([BOEING_2022_10K_pdf.md, a294691b29489acf::69])
- Note: 737-7 certification and first delivery expected in 2023; 737-10 FAA certification flight testing to begin in 2023 with first delivery in 2024.

### 787 Program
- **Current rate:** "currently producing at low rates"
- **FY2023 forecast:** "expect to gradually return to 5 per month in 2023" ([BOEING_2022_10K_pdf.md, a294691b29489acf::69])
- The return to 5/month is significant because rates below 5/month were determined to be "abnormally low" and trigger abnormal production costs. Most abnormal costs (~$2.8B cumulative estimate) are expected to be incurred by end of 2023.

### 777/777X Programs
- **Current rate:** Combined 3 per month for 777/777X
- **FY2023 forecast:** Production of the 777X-9 was **paused during 2022 and 2023** (decision made April 2022), with the pause expected to result in ~$1.5 billion of abnormal production costs expensed as incurred until 777X-9 production resumes ([BOEING_2022_10K_pdf.md, a294691b29489acf::69])
- First delivery of 777X-9 revised to 2025 (from late 2023); 777X-8 freighter first delivery expected 2027.

### 767 Program
- **Current rate:** 3 aircraft per month (combined commercial + KC-46A derivative) — no explicit change forecast for 2023 ([BOEING_2022_10K_pdf.md, a294691b29489acf::69])

### 747 Program
- **Production completed** in Q4 2022; final delivery expected in early 2023 ([BOEING_2022_10K_pdf.md, a294691b29489acf::69])

### Summary
The two most explicit FY2023 production rate changes Boeing forecast were:
1. **787: gradual return to 5 per month** (from currently low rates)
2. **737: further gradual increases** above the 31/month rate achieved in 2022

Concurrently, the **777X-9 production remained paused through 2023**, and the **747 program ended** with final delivery in early 2023. Boeing also flagged that its overall delivery ramp-up depends on stabilization of the global supply chain and labor environment ([BOEING_2022_10K_pdf.md, a294691b29489acf::54], [a294691b29489acf::56]).
- **Judge Rationale**: The agent correctly identifies 737 and 787 production increases, but incorrectly states 777X production remained paused through 2023 rather than resuming in 2023, missing one of the three programs in the gold answer.
- **Numeric Match**: None
- **Groundedness**: partial

### `financebench_id_00585` — BOEING_2022_10K (PARTIAL)

- **Question**: How does Boeing's effective tax rate in FY2022 compare to FY2021?
- **Gold Answer**: Effective tax rate in FY2022 was 0.62%, compared to  -14.76% in FY2021.
- **Agent Answer**: ## Boeing Effective Tax Rate: FY2022 vs FY2021

**Conclusion:** Boeing's effective tax rate fell sharply from **14.7% in FY2021** to **(0.6)% in FY2022** — a decline of roughly **15.3 percentage points**. In both years Boeing reported a pre-tax loss, but the tax outcome flipped from a sizable tax *benefit* in 2021 to a small tax *expense* in 2022.

### Supporting figures (from Note 4 – Income Taxes, BOEING_2022_10K)

| Years ended December 31 | 2022 | 2021 |
|---|---|---|
| Loss before income taxes (Total) | $(5,022)M | $(5,033)M |
| Total income tax expense/(benefit) | $31M | $(743)M |
| **Effective tax rate** | **(0.6)%** | **14.7%** |

[a294691b29489acf::142] (BOEING_2022_10K_pdf.md)

### Reconciliation drivers (rate reconciliation, same section)

The rate reconciliation shows why the two years diverged despite nearly identical pre-tax losses:

| Component | 2022 rate | 2021 rate |
|---|---|---|
| U.S. federal statutory tax | 21.0% | 21.0% |
| Valuation allowance | (23.9)% | (10.2)% |
| R&D credits | 4.1% | 3.8% |
| State income tax, net of federal effect | 1.8% | 1.9% |
| Tax on non-U.S. activities | (1.3)% | (0.9)% |
| CARES Act impact | 0.1% | (0.1)% |
| Other provision adjustments | (2.4)% | (0.8)% |
| **Effective tax rate** | **(0.6)%** | **14.7%** |

[a294691b29489acf::142] (BOEING_2022_10K_pdf.md)

### Key takeaway

The dominant driver of the year-over-year change was the **valuation allowance**, which swung from (10.2)% of pre-tax loss in 2021 to (23.9)% in 2022. Boeing increased its deferred tax asset valuation allowance by $739M during 2022 (from $2,423M to $3,162M), reflecting tax credits and carryforwards generated in 2022 that could not be realized. Because Boeing remained in a three-year cumulative pre-tax loss position, it could not project future income to support realization of those deferred tax assets, pushing the effective rate down to near zero (a small expense) in 2022 versus a meaningful tax benefit rate of 14.7% in 2021 [a294691b29489acf::142] (BOEING_2022_10K_pdf.md).
- **Judge Rationale**: The agent correctly identifies the 2022 rate as near zero and the 2021 outcome as a tax benefit, but its explicit rate signs are reversed relative to the gold answer (14.7% vs -14.76% for 2021 and (0.6)% vs 0.62% for 2022).
- **Numeric Match**: False
- **Groundedness**: grounded

### `financebench_id_00601` — ULTABEAUTY_2023Q4_EARNINGS (INCORRECT)

- **Question**: What drove the reduction in SG&A expense as a percent of net sales in FY2023?
- **Gold Answer**: Lower marketing expenses and leverage of incentive compensation due to higher sales. The answer here assumes FY2023 refers to the 12 months ended on January 28, 2023 (although the company refers to this period as its fiscal 2022.
- **Agent Answer**: I'll research this question about the reduction in SG&A expense as a percent of net sales in FY2023. Let me start by exploring the available documents.The user is asking about a reduction in SG&A as a percent of net sales in FY2023, but didn't specify a company. Let me look at the 2023 10-K filings available. The most likely candidate is Best Buy, which has a FY2023 10-K (Best Buy's fiscal year ends in late January/early February). Let me explore its structure.This is Best Buy's FY2023 10-K. The question is about SG&A as a percent of net sales. The MD&A "Results of Operations" section should discuss this. Let me read the relevant sections.Let me get the full TOC of the Results of Operations section to find the SG&A subsection.Now let me read the "Consolidated Results" section (76) which should contain the SG&A discussion, and the "Domestic Segment" section (78) which might also discuss SG&A.I have all the information needed to answer this question. Note that this is **Best Buy Co., Inc.** (FY2023 10-K; Best Buy's fiscal 2023 ended January 28, 2023).

## Important Clarification on the Premise

There's an important nuance to flag: **SG&A expense as a percent of revenue did NOT reduce in FY2023 — it actually increased**, while the **dollar amount of SG&A expense did decrease**. Here are the actual figures from the Consolidated Results (`BESTBUY_2023_10K_pdf.md [afb612f40d4cace6::76]`):

| Metric | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| SG&A ($M) | $7,970 | $8,635 | $7,928 |
| **SG&A as % of revenue** | **17.2%** | **16.7%** | **16.8%** |

So SG&A dollars fell ~$665M (from $8,635M to $7,970M), but the SG&A *rate* rose ~50 bps (16.7% → 17.2%) because revenue declined faster (−10.6%) than SG&A did.

## What Drove the Reduction in SG&A Expense (Dollars)

Per the Domestic Segment discussion (`BESTBUY_2023_10K_pdf.md [afb612f40d4cace6::78]`), the decrease was **primarily driven by the Domestic segment** (which accounts for the vast majority of consolidated results):

1. **Lower short-term incentive compensation expense of ~$455 million** vs. the prior year — Best Buy was below the required thresholds for most STI performance metrics in FY2023, while FY2022 had lapped STI payouts near maximum levels.
2. **Decreased store payroll expenses.**

The International segment (`BESTBUY_2023_10K_pdf.md [afb612f40d4cace6::79]`) contributed via:
3. **Lower short-term incentive compensation expense** and the **favorable impact of foreign currency exchange rates** (Canada).

## Why the SG&A *Rate* Went Up Despite Lower SG&A Dollars

Even though SG&A dollars fell, the SG&A-as-a-percent-of-revenue ratio **rose 50 bps to 17.2%** because of **decreased leverage from lower sales volume on fixed expenses** — i.e., the ~10.6% revenue decline outpaced the SG&A reduction. As Best Buy states, operating income rate declined "primarily driven by the unfavorable gross profit rate … and **decreased leverage from lower sales volume on our fixed expenses, which resulted in an unfavorable SG&A rate**" (`BESTBUY_2023_10K_pdf.md [afb612f40d4cace6::78]` and `[afb612f40d4cace6::79]`).

### Summary
- **SG&A dollars declined** in FY2023 driven mainly by ~$455M lower short-term incentive compensation, lower store payroll (Domestic), and favorable FX (International).
- **SG&A as a % of net sales actually increased** (16.7% → 17.2%) because revenue fell faster than SG&A, causing fixed-cost deleverage.
- **Judge Rationale**: The agent analyzes a different company (Best Buy) and contradicts the premise, missing the gold answer's drivers of lower marketing expenses and incentive compensation leverage from higher sales.
- **Numeric Match**: None
- **Groundedness**: ungrounded

### `financebench_id_00651` — JOHNSON_JOHNSON_2022Q4_EARNINGS (INCORRECT)

- **Question**: Is growth in JnJ's adjusted EPS expected to accelerate in FY2023?
- **Gold Answer**: No, rate of growth in adjusted EPS is expected to decelerate slightly from 3.6% in FY2022 to 3.5% in FY2023.
- **Agent Answer**: ## Answer

**Yes — at the midpoint of guidance, J&J's adjusted EPS growth is expected to modestly accelerate in FY2023**, though the low end of the range would imply a slight deceleration.

### Supporting figures (from the Q4/FY2022 earnings release)

**FY2022 actual (Adjusted EPS, diluted):**
- FY2022: **$10.15** vs. FY2021: **$9.80** → **+3.6% growth** `[11e4d750a4cc4942::3]`

**FY2023 guidance (Adjusted EPS, diluted):**
- Range: **$10.45 – $10.65**, midpoint **$10.55**
- Implied growth vs. prior year: **3.0% – 5.0%, midpoint 4.0%** `[11e4d750a4cc4942::11]`

### Comparison

| Metric | FY2022 actual | FY2023 guidance (midpoint) | FY2023 guidance (range) |
|---|---|---|---|
| Adjusted EPS (diluted) | $10.15 | $10.55 | $10.45 – $10.65 |
| YoY growth | 3.6% | 4.0% | 3.0% – 5.0% |

- **Midpoint (4.0%) > FY2022 actual (3.6%)** → modest **acceleration** of ~40 bps at the midpoint.
- However, the **low end of the range (3.0%) is below the 3.6% FY2022 actual**, so acceleration is not guaranteed across the full range — only at/above the midpoint.

### Conclusion
At the midpoint of J&J's January 2023 FY2023 guidance, adjusted diluted EPS growth is expected to **accelerate modestly from 3.6% (FY2022) to 4.0% (FY2023)**. The acceleration is slight and contingent on landing at or above the midpoint of the guided range.

*Source: JOHNSON_JOHNSON_2022Q4_EARNINGS_pdf.md — "OVERALL FINANCIAL RESULTS" `[11e4d750a4cc4942::3]` and "FULL-YEAR 2023 GUIDANCE" `[11e4d750a4cc4942::11]`.*
- **Judge Rationale**: The agent concludes acceleration to 4.0% at midpoint, contradicting the gold answer that FY2023 adjusted EPS growth decelerates slightly to 3.5%.
- **Numeric Match**: False
- **Groundedness**: ungrounded

### `financebench_id_00790` — CVSHEALTH_2022_10K (PARTIAL)

- **Question**: Is CVS Health a capital-intensive business based on FY2022 data?
- **Gold Answer**: Yes, CVS Health requires an extensive asset base to operate, which is evident from its ROA of only 1.82% in 2022 and 3.39% in 2021, though it should be noted that a significant portion of this asset base is goodwill, and CVS's fixed assets/total assets ratio is on the lower side of 5.6%.
- **Agent Answer**: I'll research CVS Health's capital intensity for FY2022. Let me start by consulting the relevant skills and exploring the document graph.I found the CVS Health 2022 10-K (document id: `20623791d2fcdd42`). Now let me get the document's table of contents to locate the financial statements needed for the capital intensity analysis.I found the key financial statements. Now let me read the Consolidated Balance Sheets, Statements of Operations, and Cash Flows to extract the data needed for capital intensity analysis.I now have all the data I need from the three core financial statements. Let me compile the capital intensity analysis for CVS Health FY2022.

## Capital Intensity Analysis — CVS Health (FY2022)

### Conclusion
**No — CVS Health is not a capital-intensive business in the traditional sense.** Its FY2022 asset base is dominated by acquisition-related goodwill and intangibles (largely from the Aetna acquisition) and working-capital items, not productive physical capital (PP&E). CapEx and PP&E are both very small fractions of revenue.

### Key FY2022 Figures (source: CVSHEALTH_2022_10K_pdf.md)

| Line item | Value | Source |
|---|---|---|
| Total revenues | $322,467M | Consolidated Stmts of Operations `[20623791d2fcdd42::204]` |
| Total assets (12/31/2022) | $228,275M | Consolidated Balance Sheets `[20623791d2fcdd42::206]` |
| Property and equipment, net | $12,873M | Consolidated Balance Sheets `[20623791d2fcdd42::206]` |
| Operating lease right-of-use assets | $17,872M | Consolidated Balance Sheets `[20623791d2fcdd42::206]` |
| Goodwill | $78,150M | Consolidated Balance Sheets `[20623791d2fcdd42::206]` |
| Intangible assets, net | $24,754M | Consolidated Balance Sheets `[20623791d2fcdd42::206]` |
| Purchases of property and equipment (CapEx) | $2,727M | Consolidated Stmts of Cash Flows `[20623791d2fcdd42::207]` |
| Depreciation and amortization | $4,247M | Consolidated Stmts of Cash Flows `[20623791d2fcdd42::207]` |
| Net income attributable to CVS Health | $4,149M | Consolidated Stmts of Operations `[20623791d2fcdd42::204]` |

### Capital Intensity Metrics

| Metric | Formula | Calculation | Result | Interpretation |
|---|---|---|---|---|
| **Asset Intensity** | Total Assets / Revenue | 228,275 / 322,467 | **0.71×** | Low — generates $1.41 of revenue per $1 of assets; typical of distribution/insurance, not capital-intensive |
| **Asset Turnover** | Revenue / Total Assets | 322,467 / 228,275 | **1.41×** | Healthy turnover, inconsistent with capital-intensive industries |
| **PP&E / Revenue** | PP&E / Revenue | 12,873 / 322,467 | **3.99%** | Very low — capital-intensive firms typically run 15–40%+ |
| **CapEx / Revenue** | CapEx / Revenue | 2,727 / 322,467 | **0.85%** | Very low — capital-intensive firms typically reinvest 5–15%+ of revenue |
| **PP&E / Total Assets** | PP&E / Total Assets | 12,873 / 228,275 | **5.64%** | PP&E is a minor slice of the asset base |
| **D&A / Revenue** | D&A / Revenue | 4,247 / 322,467 | **1.32%** | Low depreciation burden relative to revenue |
| **ROA** | Net Income / Total Assets | 4,149 / 228,275 | **1.82%** | Below the <5% "capital intensity" threshold (see caveat below) |

### Why the low ROA does NOT signal capital intensity here
The `financial-ratios` skill flags ROA < 5% as a primary indicator of capital intensity. CVS's ROA of 1.82% would trip that rule on its face, but in this case the low ROA is **not** driven by capital intensity. It is driven by two unrelated factors:

1. **Asset inflation from acquisitions:** Goodwill ($78,150M) + intangibles ($24,754M) = **$102,904M, or ~45% of total assets** — these are non-productive acquisition balances (chiefly the Aetna deal), not physical plant that generates revenue. Stripping them out, PP&E is only 5.6% of assets.
2. **Depressed 2022 earnings from one-time charges:** 2022 net income was hit by **$5,803M in opioid litigation charges** and a **$2,533M loss on assets held for sale** `[20623791d2fcdd42::204]`. Absent these, pre-tax income would have been materially higher, and the "capital intensity" ROA signal would largely disappear.

### Composition of the asset base (FY2022)
- Goodwill + intangibles (acquisition-driven): **~45%** of total assets
- Working capital (receivables $27,276M + inventory $19,090M): **~20%**
- Operating lease ROU assets (retail store footprint): **~7.8%**
- **PP&E (productive physical capital): only ~5.6%**

### Bottom line
By every conventional capital-intensity measure — PP&E/Revenue (3.99%), CapEx/Revenue (0.85%), PP%E/Total Assets (5.6%), and Asset Turnover (1.41×) — CVS Health operates a **low-physical-capital, distribution-and-insurance business model**, not a capital-intensive one. The company's large balance sheet is built on acquisition goodwill/intangibles and working capital, not fixed productive assets. The superficially low ROA is an artifact of acquisition accounting and 2022 one-time litigation charges, not of capital intensity.
- **Judge Rationale**: The agent correctly calculates the same FY2022 figures (ROA 1.82%, PP&E/total assets 5.6%) and notes the goodwill/intangibles caveat, but reaches the opposite qualitative conclusion from the gold answer.
- **Numeric Match**: True
- **Groundedness**: grounded

### `financebench_id_01328` — PEPSICO_2022_10K (INCORRECT)

- **Question**: What is the quantity of restructuring costs directly outlined in Pepsico's income statements for FY2022? If restructuring costs are not explicitly outlined then state 0.
- **Gold Answer**: Pepsico's restructuring costs in FY2022 amounted to $411 million .
- **Agent Answer**: ## Answer

**$0** — PepsiCo's FY2022 Consolidated Statement of Income does not contain a separately outlined "restructuring costs" line item.

### Supporting Evidence

The Consolidated Statement of Income for the fiscal year ended December 31, 2022 (PEPSICO_2022_10K_pdf.md [b4a332ca797b2113::141]) presents the following operating expense lines between Gross profit and Operating Profit:

| Line Item | 2022 |
|---|---|
| Gross profit | $45,816 |
| Selling, general and administrative expenses | $34,459 |
| Gain associated with the Juice Transaction (see Note 13) | $(3,321) |
| Impairment of intangible assets (see Notes 1 and 4) | $3,166 |
| **Operating Profit** | $11,512 |

There is no "Restructuring costs" (or similarly titled) line item directly outlined on the face of the income statement. Per the question's instruction, since restructuring costs are not explicitly outlined, the quantity is **$0**.

(Note: PepsiCo does discuss productivity/restructuring-related charges within "Items Affecting Comparability" in the MD&A and notes, but these are not presented as a discrete line on the income statement face itself.)
- **Judge Rationale**: The gold answer states FY2022 restructuring costs were $411 million, while the agent answered $0 because it did not find a separate income statement line item, so the substantive value is wrong.
- **Numeric Match**: False
- **Groundedness**: grounded

### `financebench_id_01911` — MGMRESORTS_2022Q4_EARNINGS (INCORRECT)

- **Question**: What was MGM's interest coverage ratio using FY2022 Adjusted EBIT as the numerator and annual Interest Expense as the denominator?
- **Gold Answer**: As adjusted EBIT is negative, coverage ratio is zero
- **Agent Answer**: I'll answer this by navigating the Document Graph for MGM's FY2022 filings. Let me start by checking the relevant skill and listing available documents.I found MGM Resorts' FY2022 filings. The question involves a Non-GAAP measure (Adjusted EBIT), so I'll check both the 10-K and the Q4 Earnings Release, plus the financial-ratios skill for the interest coverage ratio convention.I have the ratio convention: Interest Coverage = EBIT / Interest Expense. The question specifies "FY2022 Adjusted EBIT" (a Non-GAAP measure MGM uses) as the numerator and annual Interest Expense as denominator. Let me read the earnings release financial tables and search for Adjusted EBIT in the 10-K.The earnings release reconciliation shows "Adjusted EBITDAR" (their primary Non-GAAP metric), not "Adjusted EBIT" directly. However, the question specifically asks for "Adjusted EBIT." Let me search the 10-K's MD&A section to see how MGM defines "Adjusted EBIT" and find the FY2022 figure.Let me look at the MD&A "Operating Results – Details of Certain Charges" section and search the 10-K specifically for "Adjusted EBIT" definitions.I found the "Non-GAAP Measures" section in the 10-K. Let me read it to find MGM's "Adjusted EBIT" definition and the FY2022 figure.I now have all the components needed. Let me verify my reading of the key figures and the interest expense line, which both the 10-K reconciliation and the earnings release income statement confirm.

## Answer

**MGM's FY2022 interest coverage ratio ≈ 5.88×** (using MGM's reported non-GAAP Adjusted EBITDAR as the "Adjusted EBIT" numerator, over annual interest expense).

### Calculation
| Component | FY2022 Amount (in thousands) | Source |
|---|---|---|
| Adjusted EBITDAR (MGM's non-GAAP "adjusted earnings" measure) | $3,497,254 | `MGMRESORTS_2022_10K_pdf.md` [f6538fcc36dc2083::82]; `MGMRESORTS_2022Q4_EARNINGS_pdf.md` [051c9442758473f0::28] |
| Interest expense, net of amounts capitalized (annual) | $594,954 | `MGMRESORTS_2022_10K_pdf.md` [f6538fcc36dc2083::82]; income statement in `MGMRESORTS_2022Q4_EARNINGS_pdf.md` [051c9442758473f0::24] |

**Interest Coverage = $3,497,254 ÷ $594,954 ≈ 5.88×**

### Interpretation note (important)
MGM does **not** report a line item literally called "Adjusted EBIT." Its headline non-GAAP earnings measure is **"Adjusted EBITDAR"** (earnings before Interest, Taxes, D&A, preopening, property transactions/REIT gains, triple-net rent, and RE-venture income), defined and reconciled in the 10-K's Non-GAAP Measures section (`MGMRESORTS_2022_10K_pdf.md` [f6538fcc36dc2083::82]) and the Q4 2022 earnings release (`MGMRESORTS_2022Q4_EARNINGS_pdf.md` [051c9442758473f0::28]). I used this figure as the "Adjusted EBIT" numerator since it is MGM's only reported "adjusted earnings" metric.

For completeness, the reconciliation from GAAP Operating Income to Adjusted EBITDAR (FY2022, $ thousands):

| Reconciling item | FY2022 ($000) |
|---|---|
| Operating income (GAAP) | 1,439,372 |
| + Preopening and start-up expenses | 1,876 |
| − Property transactions, net (Mirage sale gain) | (1,036,997) |
| + Depreciation and amortization | 3,482,050 |
| − Gain on REIT transactions, net (VICI) | (2,277,747) |
| + Triple-net operating lease & ground lease rent expense | 1,950,566 |
| − Income from unconsolidated affiliates (RE ventures) | (61,866) |
| **= Adjusted EBITDAR** | **3,497,254** |

**Alternative (strict) interpretation:** If one derives a strict "Adjusted EBIT" by also stripping the D&A add-back and the triple-net rent add-back out of Adjusted EBITDAR (i.e., Adjusted EBIT = Adjusted EBITDAR − D&A − Rent = 3,497,254 − 3,482,050 − 1,950,566 = **−$1,935,362 thousand**), the result is **negative** — driven by the $2.5B non-cash amortization of the MGM Grand Paradise gaming concession (useful-life change) and the removal of the $2.3B VICI REIT gain and $1.0B Mirage sale gain that had inflated GAAP operating income. Under the standard convention (negative EBIT ⇒ coverage = 0), a strict Adjusted EBIT would imply **0× coverage**. The 5.88× figure above is the meaningful, MGM-reported version.
- **Judge Rationale**: The gold answer states that because FY2022 Adjusted EBIT is negative, the interest coverage ratio is zero, whereas the agent reports approximately 5.88x using Adjusted EBITDAR and only mentions the zero-coverage alternative as a secondary interpretation.
- **Numeric Match**: False
- **Groundedness**: partial

### `financebench_id_01936` — AMCOR_2023Q2_10Q (PARTIAL)

- **Question**: What is the nature & purpose of AMCOR's restructuring liability as oF Q2 of FY2023 close?
- **Gold Answer**: 87% of the total restructuring liability is related Employee liabilities.
- **Agent Answer**: I'll navigate to the AMCOR Q2 FY2023 10-Q filing to find the restructuring liability details.I found the AMCOR Q2 FY2023 10-Q. The restructuring liability details should be in Note 6 (Restructuring) and Note 3 (Restructuring and Other Related Activities, Net). Let me read both.Let me also check Note 3 for additional context on restructuring and other related activities.Let me also check Note 16 (Subsequent Events) and Note 15 (Other Matters) for any additional context on the Russian business disposal and the future restructuring initiatives mentioned.Let me also check Note 4 (Held for Sale) and Note 5 (Acquisitions and Disposals) for the full context on the Russian business, which is central to the restructuring activities.Let me also check the balance sheet sections to see how the restructuring liability is recorded, and the MD&A section on restructuring for additional narrative.I now have comprehensive information to answer the question. Let me present the analysis.

# Nature & Purpose of AMCOR's Restructuring Liability as of Q2 FY2023 Close (December 31, 2022)

## Summary

As of Q2 FY2023 close (December 31, 2022), Amcor plc's restructuring liability totaled **$93 million**, a decline of $25 million from the $118 million balance at the start of the fiscal year (June 30, 2022). The liability primarily reflects ongoing obligations from Amcor's **2019 restructuring/integration plan** tied to the acquisition of Bemis operations (substantially completed at the end of fiscal year 2022), with a smaller portion related to **Russia-Ukraine conflict** restructuring activities [AMCOR_2023Q2_10Q_pdf.md [3a907fa352c08c21::24]].

## Nature & Purpose

Per Note 6 ("Restructuring"), the liability consists of three cost categories, all primarily attributable to Amcor's **Flexibles reportable segment** [3a907fa352c08c21::24]:

| Component | Purpose | Balance at Dec 31, 2022 |
|---|---|---|
| **Employee Costs** | Severance and workforce reductions from the Bemis integration | $81M |
| **Fixed Asset Related Costs** | Costs associated with exiting/consolidating facilities | $2M |
| **Other Costs** | Ancillary restructuring charges | $10M |
| **Total** | | **$93M** |

The primary driver of the expense activity in the period was the **2019 integration plan** following the Bemis acquisition; the six-month expense of $3 million (vs. $18 million in the prior-year period) reflects that this plan was substantially completed by the end of FY2022 [3a907fa352c08c21::24]. A secondary driver was restructuring related to the **Russia-Ukraine conflict**, which culminated in the sale of Amcor's three Russian manufacturing facilities on December 23, 2022 (yielding a $215M pre-tax gain on disposal) [3a907fa352c08c21::19, ::23].

## Liability Rollforward (Six Months Ended December 31, 2022) [3a907fa352c08c21::24]

| ($ in millions) | Employee Costs | Fixed Asset | Other | Total |
|---|---|---|---|---|
| Balance at June 30, 2022 | $97 | $3 | $18 | **$118** |
| Net charges to earnings | 2 | — | — | 2 |
| Cash paid | (16) | (1) | (8) | (25) |
| Reversal of unused amounts | (2) | — | — | (2) |
| **Balance at Dec 31, 2022** | **$81** | **$2** | **$10** | **$93** |

## Balance Sheet Classification & Timing

- The accruals are recorded on the condensed consolidated balance sheets under **"other current liabilities"** and **"other non-current liabilities"** [3a907fa352c08c21::24].
- Amcor expects the **majority of the liability to be paid within the next twelve months** (i.e., by end of FY2023), indicating most of the $93M is classified as current [3a907fa352c08c21::24].
- On the income statement, these costs flow through the line item **"Restructuring and other related activities, net"** (which for the six months ended Dec 31, 2022 was a $212M net positive, dominated by the $215M Russian disposal gain, less $3M of restructuring expenses) [3a907fa352c08c21::19, ::70].

## Subsequent Event Context

On February 7, 2023, the Board approved investing **$110M–$130M** of the cash received from the Russian business sale in a "range of additional initiatives to partly offset divested earnings," signaling that restructuring/redeployment activities would continue beyond the balance sheet date [3a907fa352c08c21::45].
- **Judge Rationale**: The agent provides a comprehensive breakdown of the restructuring liability, including the $81M employee costs balance, but does not explicitly state that employee liabilities comprise 87% of the total; however, this can be inferred from the provided figures ($81M/$93M), which the agent gives, making the answer largely correct but not fully articulated as the gold answer.
- **Numeric Match**: None
- **Groundedness**: grounded

### `financebench_id_02119` — JPMORGAN_2021Q1_10Q (PARTIAL)

- **Question**: If JPM went bankrupted by the end by 2021 Q1 and liquidated all of its assets to pay its shareholders, how much could each shareholder get?
- **Gold Answer**: They could receive $66.56 per share.
- **Agent Answer**: I'll answer this question about JPM's liquidation value per share as of end of Q1 2021. Let me first consult the relevant skills, then navigate the document graph.I found the JPMorgan Q1 2021 10-Q document. This is a liquidation value per share question, so I need to find the balance sheet (stockholders' equity, goodwill, intangibles, and common shares outstanding). Let me get the document's section tree.I need the Consolidated Balance Sheet for stockholders' equity, goodwill, intangibles, and common shares outstanding. The financial statements are likely in sections 188-192. Let me also check the Goodwill note.I have the balance sheet. Now I need the breakdown of "Goodwill, MSRs and other intangible assets" ($54,588M) to separate goodwill from intangibles for the tangible BVPS calculation. Let me search for more detail.The search didn't land on the JPM Q1 2021 document. Let me read the Goodwill note section and the mortgage servicing rights section directly.Let me check the sections between the goodwill note header and the MSR section for the goodwill breakdown.I now have all the data needed. Let me compile the answer.

## Liquidation Value Per Share — JPMorgan Chase (Q1 2021)

If JPMorgan Chase had liquidated all assets at book value as of March 31, 2021, each common shareholder could receive:

### 1. Common Book Value Per Share ≈ **$82.31**

**Calculation:**
- Total stockholders' equity: $280,714M
- Less: Preferred stock: ($31,563M)
- **Common equity: $249,151M**
- Common shares outstanding: 4,104,933,895 issued − 1,077,805,783 treasury = **3,027,128,112 shares**
- $249,151M ÷ 3,027,128,112 shares = **$82.31 per share**

### 2. Tangible Book Value Per Share ≈ **$64.27**

**Calculation:**
- Common equity: $249,151M
- Less: Goodwill, MSRs & other intangible assets: ($54,588M)
  - Goodwill: $49,243M (Note 14)
  - MSRs (fair value): $4,470M
  - Other intangibles: $875M (residual)
- **Tangible common equity: $194,563M**
- $194,563M ÷ 3,027,128,112 shares = **$64.27 per share**

### Key Figures & Sources

| Item | Value (March 31, 2021) | Source |
|---|---|---|
| Total stockholders' equity | $280,714M | Consolidated balance sheet `[71f9b9350ac5651c::190]` (JPMORGAN_2021Q1_10Q_pdf.md) |
| Preferred stock | $31,563M | Consolidated balance sheet `[71f9b9350ac5651c::190]` |
| Common stock issued | 4,104,933,895 shares | Consolidated balance sheet `[71f9b9350ac5651c::190]` |
| Treasury stock | 1,077,805,783 shares | Consolidated balance sheet `[71f9b9350ac5651c::190]` |
| Goodwill, MSRs & other intangibles | $54,588M | Consolidated balance sheet `[71f9b9350ac5651c::190]` |
| Goodwill (component) | $49,243M | Note 14 – Goodwill `[71f9b9350ac5651c::303]` |
| MSRs fair value (component) | $4,470M | Note 14 – MSRs `[71f9b9350ac5651c::305]` |

### Interpretation

- **Common BVPS ($82.31)** represents what each shareholder would receive if all assets were liquidated at book value and all liabilities (including preferred stock) were paid off — i.e., the accounting book value of common equity.
- **Tangible BVPS ($64.27)** is the more conservative liquidation value, stripping out goodwill and intangible assets ($54,588M) that may have little or no realizable value in a forced liquidation. This is the figure most analysts would consider the "true" liquidation floor.

**Bottom line:** In a bankruptcy liquidation at book value, each JPM common shareholder would receive approximately **$82.31 per share** (common book value) or, more conservatively, **$64.27 per share** (tangible book value, excluding goodwill and intangibles).
- **Judge Rationale**: The agent identifies tangible book value per share as the relevant liquidation measure, but its calculated $64.27 (or $82.31) does not match the gold answer of $66.56 per share.
- **Numeric Match**: False
- **Groundedness**: grounded

### `financebench_id_02419` — Pfizer_2023Q2_10Q (INCORRECT)

- **Question**: As of Q2'2023, is Pfizer spinning off any large business segments?
- **Gold Answer**: Yes, it's spinning off Upjohn.
- **Agent Answer**: I'll research this question about Pfizer's Q2 2023 business segment spin-offs. Let me start by consulting the relevant skill and exploring the document graph.I found the Pfizer Q2 2023 10-Q documents. Let me explore the document outline to find sections related to business segment spin-offs.I found the document outline. The key section for this question is "Note 2. Acquisitions, Discontinued Operations, Equity-Method Investment and Research and Development Arrangement" with a subsection "B. Discontinued Operations". Let me read this section along with the Q2 2023 performance overview.I found the discontinued operations section, but it references a 2020 spin-off (Upjohn/Viatris). The question is asking about Q2 2023 specifically. Let me search for more recent spin-off announcements in the document.I see a reference to the Haleon/Consumer Healthcare JV in the Equity-Method Investment section. Let me read this section along with the related section that mentioned the consumer healthcare business.I now have the complete picture. The Haleon/Consumer Healthcare JV demerger was completed by GSK on July 18, 2022 (before Q2 2023), and the Upjohn/Viatris spin-off was in 2020. Let me also check the MD&A overview/strategy section for any mention of a planned spin-off as of Q2 2023.Let me check the segment information section and the MD&A overview to be thorough about any planned spin-offs as of Q2 2023.I now have a comprehensive picture of Pfizer's spin-off and divestiture activities as of Q2 2023. Based on my review of the Pfizer Q2 2023 10-Q, I can provide a definitive answer.

## Answer

**No, as of Q2 2023, Pfizer was not spinning off any large business segments.** The major spin-offs/separations Pfizer had undertaken were already completed before the Q2 2023 reporting period (quarter ended July 2, 2023):

### Completed Spin-Offs (Prior to Q2 2023)

1. **Upjohn / Viatris Spin-Off (2020)** — Pfizer combined its Upjohn business with Mylan to form Viatris in 2020. As of Q2 2023, this only appears as post-close adjustments: "net amounts due to Viatris were $25 million as of July 2, 2023" under interim transition/master services agreements (TSAs/MSAs) (`Pfizer_2023Q2_10Q_pdf.md [4cb9bd30b032f3cb::21]`). Pfizer noted it expected to incur ~$700 million in total separation costs, of which ~90% had been incurred through Q2 2023 (`Pfizer_2023Q2_10Q_pdf.md [4cb9bd30b032f3cb::134]`).

2. **Haleon / Consumer Healthcare JV Demerger (July 18, 2022)** — GSK completed the demerger of the Consumer Healthcare JV (jointly owned by GSK and Pfizer), which became Haleon, an independent publicly-traded company. Pfizer continues to hold a **32% equity stake** (an equity-method investment carried at $11.2 billion as of July 2, 2023; fair value $12.1 billion) (`Pfizer_2023Q2_10Q_pdf.md [4cb9bd30b032f3cb::22]`, `[4cb9bd30b032f3cb::23]`). This was not a Pfizer-led spin-off but rather a GSK-led demerger in which Pfizer became a minority shareholder.

### Discontinued Operations — Only Post-Close Adjustments
The Discontinued Operations note explicitly states these relate only to "post-close adjustments for previously divested businesses" and that amounts under interim agreements (TSAs/MSAs) "were not material" for Q2 2023 (`Pfizer_2023Q2_10Q_pdf.md [4cb9bd30b032f3cb::21]`). No new large segment was classified as held-for-sale or discontinued operations.

### Other Business Development (Not Spin-Offs)
As of Q2 2023, Pfizer's notable corporate actions were **acquisitions/divestitures of product portfolios**, not segment spin-offs:
- **Proposed acquisition of Seagen** (announced 2023) — an acquisition, not a divestiture (`Pfizer_2023Q2_10Q_pdf.md [4cb9bd30b032f3cb::134]`).
- **Divestiture of early-stage rare disease gene therapy portfolio to Alexion** (announced July 2023, after quarter-end) — a product portfolio sale for up to $1 billion plus royalties, expected to close Q3 2023 (`Pfizer_2023Q2_10Q_pdf.md [4cb9bd30b032f3cb::134]`).

### Conclusion
As of Q2 2023, Pfizer was **not spinning off any large business segments**. Its two major separations — Upjohn/Viatris (2020) and the Consumer Healthcare JV/Haleon demerger (July 2022) — were already completed, and the Q2 2023 filing only reflects residual post-close adjustments and ongoing separation cost wind-down from those prior transactions.
- **Judge Rationale**: The agent says Pfizer was not spinning off any large business segments as of Q2 2023, directly contradicting the gold answer that it was spinning off Upjohn, which the gold evidence supports as an ongoing separation.
- **Numeric Match**: None
- **Groundedness**: ungrounded
